Zobrazeno 1 - 10
of 77
pro vyhledávání: '"Colin G, Miller"'
Autor:
Colin T. Shearn, Aimee L. Anderson, Colin G. Miller, Reed C. Noyd, Michael W. Devereaux, Nata Balasubramaniyan, David J. Orlicky, Edward E. Schmidt, Ronald J. Sokol
Publikováno v:
Hepatology Communications, Vol 7, Iss 1, Pp e0020-e0020 (2023)
Background and Aims:. Cholestatic liver diseases, including primary sclerosing cholangitis, are characterized by periportal inflammation with progression to hepatic fibrosis and ultimately cirrhosis. We recently reported that the thioredoxin antioxid
Externí odkaz:
https://doaj.org/article/65bdde1608a44f779026293984db4f20
Autor:
Colin G. Miller, Henning Grønbæk, Irene Virgolini, Andreas Kjaer, Pierre Terve, Shadfar Bahri, Peter Iversen, Hanna Svirydenka, Thomas Rohban, Sandy McEwan
Publikováno v:
EJNMMI Research, Vol 11, Iss 1, Pp 1-11 (2021)
Abstract Background 68Ga-satoreotide trizoxetan is a novel somatostatin receptor antagonist exhibiting higher tumour-to-background ratios and sensitivity compared to 68Ga-DOTATOC. This randomised, 2 × 3 factorial, phase II study aimed to confirm the
Externí odkaz:
https://doaj.org/article/4c8b1bb0808c480fadaf97e8afe9d6a7
Autor:
Colin T Shearn, Aimee L Anderson, Michael W Devereux, David J Orlicky, Cole Michel, Dennis R Petersen, Colin G Miller, Sanjiv Harpavat, Edward E Schmidt, Ronald J Sokol
Publikováno v:
PLoS ONE, Vol 17, Iss 11, p e0276879 (2022)
Inflammatory cholestatic liver diseases, including Primary Sclerosing Cholangitis (PSC), are characterized by periportal inflammation with progression to cirrhosis. The objective of this study was to examine interactions between oxidative stress and
Externí odkaz:
https://doaj.org/article/ce15a1ec4a624b35aa47d9ec04c0050d
Autor:
Deepti Talwar, Colin G. Miller, Justus Grossmann, Lukasz Szyrwiel, Torsten Schwecke, Vadim Demichev, Ana-Matea Mikecin Drazic, Anand Mayakonda, Pavlo Lutsik, Carmen Veith, Michael D. Milsom, Karin Müller-Decker, Michael Mülleder, Markus Ralser, Tobias P. Dick
Publikováno v:
Nature Metabolism. 5:660-676
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is known to contain an active-site cysteine residue undergoing oxidation in response to hydrogen peroxide, leading to rapid inactivation of the enzyme. Here we show that human and mouse cells expressin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f4874348d43578ad40f44fe3760e1e2d
https://doi.org/10.1038/s42255-023-00781-3
https://doi.org/10.1038/s42255-023-00781-3
Autor:
Justin R. Prigge, Lucia Coppo, Sebastin S. Martin, Fernando Ogata, Colin G. Miller, Michael D. Bruschwein, David J. Orlicky, Colin T. Shearn, Jean A. Kundert, Julia Lytchier, Alix E. Herr, Åse Mattsson, Matthew P. Taylor, Tomas N. Gustafsson, Elias S.J. Arnér, Arne Holmgren, Edward E. Schmidt
Publikováno v:
Cell Reports, Vol 19, Iss 13, Pp 2771-2781 (2017)
Energetic nutrients are oxidized to sustain high intracellular NADPH/NADP+ ratios. NADPH-dependent reduction of thioredoxin-1 (Trx1) disulfide and glutathione disulfide by thioredoxin reductase-1 (TrxR1) and glutathione reductase (Gsr), respectively,
Externí odkaz:
https://doaj.org/article/608638e94517493f8c9dd7af8d0965f9
Autor:
Colin G. Miller, Jean A. Kundert, Justin R. Prigge, Julie A. Amato, Allison E. Perez, Lucia Coppo, Gabrielle N. Rizzo, Michael P. Kavanaugh, David J. Orlicky, Colin T. Shearn, Edward E. Schmidt
Publikováno v:
Antioxidants, Vol 10, Iss 3, p 359 (2021)
Cellular oxidants are primarily managed by the thioredoxin reductase-1 (TrxR1)- and glutathione reductase (Gsr)-driven antioxidant systems. In mice having hepatocyte-specific co-disruption of TrxR1 and Gsr (TrxR1/Gsr-null livers), methionine cataboli
Externí odkaz:
https://doaj.org/article/98510a8d188d4921848458dea2409ac7
Autor:
Thomas Rohban, Henning Grønbæk, Colin G. Miller, Sandy McEwan, Andreas Kjaer, Pierre Terve, Hanna Svirydenka, Irene Virgolini, Shadfar Bahri, Peter Iversen
Publikováno v:
EJNMMI Research, Vol 11, Iss 1, Pp 1-11 (2021)
EJNMMI Research
Miller, C G, Grønbæk, H, Virgolini, I, Kjaer, A, Terve, P, Bahri, S, Iversen, P, Svirydenka, H, Rohban, T & McEwan, S 2021, ' A novel read methodology to evaluate the optimal dose of 68 Ga-satoreotide trizoxetan as a PET imaging agent in patients with gastroenteropancreatic neuroendocrine tumours : a phase II clinical trial ', EJNMMI Research, vol. 11, no. 1, 84, pp. 1-11 . https://doi.org/10.1186/s13550-021-00819-1
Miller, C G, Grønbæk, H, Virgolini, I, Kjaer, A, Terve, P, Bahri, S, Iversen, P, Svirydenka, H, Rohban, T & McEwan, S 2021, ' A novel read methodology to evaluate the optimal dose of 68 Ga-satoreotide trizoxetan as a PET imaging agent in patients with gastroenteropancreatic neuroendocrine tumours : a phase II clinical trial ', EJNMMI research, vol. 11, no. 84, 84 . https://doi.org/10.1186/s13550-021-00819-1
EJNMMI Research
Miller, C G, Grønbæk, H, Virgolini, I, Kjaer, A, Terve, P, Bahri, S, Iversen, P, Svirydenka, H, Rohban, T & McEwan, S 2021, ' A novel read methodology to evaluate the optimal dose of 68 Ga-satoreotide trizoxetan as a PET imaging agent in patients with gastroenteropancreatic neuroendocrine tumours : a phase II clinical trial ', EJNMMI Research, vol. 11, no. 1, 84, pp. 1-11 . https://doi.org/10.1186/s13550-021-00819-1
Miller, C G, Grønbæk, H, Virgolini, I, Kjaer, A, Terve, P, Bahri, S, Iversen, P, Svirydenka, H, Rohban, T & McEwan, S 2021, ' A novel read methodology to evaluate the optimal dose of 68 Ga-satoreotide trizoxetan as a PET imaging agent in patients with gastroenteropancreatic neuroendocrine tumours : a phase II clinical trial ', EJNMMI research, vol. 11, no. 84, 84 . https://doi.org/10.1186/s13550-021-00819-1
Background 68Ga-satoreotide trizoxetan is a novel somatostatin receptor antagonist exhibiting higher tumour-to-background ratios and sensitivity compared to 68Ga-DOTATOC. This randomised, 2 × 3 factorial, phase II study aimed to confirm the optimal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d254e7679d4aa8dbac9338fa8185578
https://doaj.org/article/4c8b1bb0808c480fadaf97e8afe9d6a7
https://doaj.org/article/4c8b1bb0808c480fadaf97e8afe9d6a7
Autor:
Guenther Brueggenwerth, Richard C. Walovitch, Colin G Miller, Klaus Noever, Robert Ford, David L. Raunig, Annette Schmid, Ivalina Hristova, Michael O'Neal, Michael O’Connor
Publikováno v:
Therapeutic Innovation & Regulatory Science. 55:1122-1138
Though many clinical trials rely on medical image evaluations for primary or key secondary endpoints, the methods to monitor reader performance are all too often mired in the legacy use of adjudication rates. If misused, this simple metric can be mis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1c7d1004904d22c1a6eaac839912d3ff
https://doi.org/10.1007/s43441-021-00317-5
https://doi.org/10.1007/s43441-021-00317-5
Autor:
Colin G Miller, Liz Kuney, Michael O’Connor, Richard C. Walovitch, Annette Schmid, Robert W. Ford, Josy Breuer, Robert Ford, Guenther Brueggenwerth, David L. Raunig
Publikováno v:
Therapeutic Innovation & Regulatory Science
The debate over human visual perception and how medical images should be interpreted have persisted since X-rays were the only imaging technique available. Concerns over rates of disagreement between expert image readers are associated with much of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6681f8527778526cd59b6e3491cda7a
https://doi.org/10.1007/s43441-021-00316-6
https://doi.org/10.1007/s43441-021-00316-6
Autor:
Ulrich Knigge, Shadfar Bahri, Johannes Czernin, Peter Iversen, Andreas Kjaer, Esben Andreas Carlsen, Christine Powell, Johanna Maffey-Steffan, Henning Grønbæk, Irene Virgolini, Sandy McEwan, Colin G. Miller, Mathias Loft, Thomas Rohban
Publikováno v:
Virgolini, I, Bahri, S, Kjaer, A, Gronbaek, H, Iversen, P, Carlsen, E A, Loft, M, Knigge, U, Maffey-Steffan, J, Powell, C, Miller, C G, Rohban, T, McEwan, S & Czernin, J 2022, ' A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for 68 Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors ', Journal of Nuclear Medicine, vol. 63, no. 3, pp. 376-383 . https://doi.org/10.2967/jnumed.121.261936
Virgolini, I, Bahri, S, Kjaer, A, Gronbaek, H, Iversen, P, Carlsen, E A, Loft, M, Knigge, U, Maffey-Steffan, J, Powell, C, Miller, C G, Rohban, T, McEwan, S & Czernin, J 2022, ' A randomised, factorial phase II study to determine the optimal dosing regimen for 68 Ga-satoreotide trizoxetan as an imaging agent in patients with gastroenteropancreatic neuroendocrine tumours ', Journal of nuclear medicine : official publication, Society of Nuclear Medicine, vol. 63, no. 3 . https://doi.org/10.2967/jnumed.121.261936
Virgolini, I, Bahri, S, Kjaer, A, Gronbaek, H, Iversen, P, Carlsen, E A, Loft, M, Knigge, U, Maffey-Steffan, J, Powell, C, Miller, C G, Rohban, T, McEwan, S & Czernin, J 2022, ' A randomised, factorial phase II study to determine the optimal dosing regimen for 68 Ga-satoreotide trizoxetan as an imaging agent in patients with gastroenteropancreatic neuroendocrine tumours ', Journal of nuclear medicine : official publication, Society of Nuclear Medicine, vol. 63, no. 3 . https://doi.org/10.2967/jnumed.121.261936
68Ga-satoreotide trizoxetan is a novel somatostatin receptor antagonist associated with high sensitivity and reproducibility in neuroendocrine tumour (NET) detection and localisation. However, the optimal peptide mass and radioactivity ranges for 68G
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f46b7d8b3fed34544124a81cf18e8ced
https://pure.au.dk/portal/da/publications/a-randomized-factorial-phase-ii-study-to-determine-the-optimal-dosing-regimen-for-68gasatoreotide-trizoxetan-as-an-imaging-agent-in-patients-with-gastroenteropancreatic-neuroendocrine-tumors(efd7ada3-d130-4069-aa7e-652d008e0f37).html
https://pure.au.dk/portal/da/publications/a-randomized-factorial-phase-ii-study-to-determine-the-optimal-dosing-regimen-for-68gasatoreotide-trizoxetan-as-an-imaging-agent-in-patients-with-gastroenteropancreatic-neuroendocrine-tumors(efd7ada3-d130-4069-aa7e-652d008e0f37).html
